📰 Alligator Bioscience News
Alligator Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alligator Bioscience. Real-time updates on events, politics, business and more.
May 24, 2024
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) support continued development of mitazalimab in a randomized confir...
May 24, 2024
Alligator Bioscience AB announced that two clinical abstracts on its lead drug candidate mitazalimab, a best- in-class CD40 agonist, in first line metastatic pancreatic cancer will be presented in a...
May 23, 2024
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months)
September 7, 2023
WASHINGTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Immuno-Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence of cancer, advancements in cancer research, the growing demand for personalized medicine, increased research and development activities in the field of immuno-oncology, as well as advancements in technology and supportive regulatory frameworks. According to Vantage Market Research, the global Immuno-O
August 26, 2023
The European Medicines Agency has granted orphan drug designation to mitazalimab for use in patients with pancreatic cancer.
June 28, 2023
 SmiLe IncubatorView in browser Strong team behind the new SmiLe company Uptake BioPress release2023-06-28 11:05Anki Malmborg Hager, CEO of Uptake Bio Lund Sweden – Uptake Bio is developing revolutionary radioimmunotherapy drugs that have the ability to target radiotherapy to specific cancer cel...
June 27, 2023
Frontline treatment with the combination of the CD40-directed monoclonal antibody agonist mitazalimab and modified FOLFIRINOX continued to produce responses in patients with metastatic pancreatic ductal adenocarcinoma.
May 22, 2023
The FDA has granted an orphan drug designation to mitazalimab for use as a potential therapeutic option in patients with pancreatic cancer.
May 4, 2023
Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic cancer. Then, the first patient was dosed in a phase I study for... | May 4, 2023
April 27, 2023
Therapy is being used during pivotal phase 1 study into patients with pancreatic cancer - News - PharmaTimes